Cumberland Pharmaceuticals (CPIX) Q1 2026 earnings summary

Executive summary

• Net revenues for Q1 2026 were $9.1 million, representing a 5% year-over-year increase when excluding a prior $3 million milestone payment, but down from $11.7 million in Q1 2025 due to the absence of that milestone.

• Announced a transformational agreement to sell the branded U.S. commercial business and FDA-approved brands to Apotex for $100 million, plus $9 million in inventory and milestone payments, pending shareholder approval.

• The company will retain its development pipeline, majority ownership in Cumberland Emerging Technologies, and will refocus on advancing innovative and orphan drug candidates, particularly the ifetroban pipeline for rare diseases.

Financial highlights

• Net loss for Q1 2026 was $3.3 million; adjusted loss was $1.9 million or $0.13 per share after non-cash expenses.

• Positive cash flow from operations of $387,000 to $400,000 in Q1; cash and cash equivalents were $11 million as of March 31, 2026.

• As of March 31, 2026: $71 million in assets, $49.7 million in liabilities, and $21.6 million in shareholders' equity.

• Operating expenses totaled $12.3 million for the quarter; operating loss was $3.1 million.

• Working capital was negative at $(1.7) million at quarter-end.

Outlook and guidance

• No longer targeting double-digit revenue growth for 2026 due to the pending Apotex transaction; focus will shift to pipeline and orphan drug development, especially ifetroban.

• Expenses expected to decrease significantly post-transaction as Apotex assumes brand-related costs; clinical spending to remain stable.

• The company anticipates continued minimal income tax payments due to significant net operating loss carryforwards.

• Fast Track Designation was granted by the FDA for ifetroban in Duchenne muscular dystrophy, accelerating its development.